MX2022013182A - Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. - Google Patents

Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.

Info

Publication number
MX2022013182A
MX2022013182A MX2022013182A MX2022013182A MX2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A
Authority
MX
Mexico
Prior art keywords
treatment
egfr
antibody
cancers
cancer
Prior art date
Application number
MX2022013182A
Other languages
English (en)
Inventor
Ernesto Isaac Wasserman
Cornelis Jacob Johannes George Bol
Szabolcs Fatrai
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2022013182A publication Critical patent/MX2022013182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a medios y métodos en el tratamiento del cáncer. La descripción en particular se refiere a un método para tratar un cáncer en un individuo con un anticuerpo que se une a LGR5 y EGFR. La invención se refiere además a la combinación para su uso en tales métodos y a la combinación para su uso en la manufactura de un medicamento para el tratamiento de cáncer gastrointestinal. Tales anticuerpos son particularmente útiles en el tratamiento de cáncer de unión gástrica, esofágica o gastro-esofágica.
MX2022013182A 2020-04-24 2021-04-23 Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. MX2022013182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2025425 2020-04-24
PCT/NL2021/050267 WO2021215926A1 (en) 2020-04-24 2021-04-23 Treatment of cancers with an antibody that binds lgr5 and egfr

Publications (1)

Publication Number Publication Date
MX2022013182A true MX2022013182A (es) 2023-01-16

Family

ID=70918928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013182A MX2022013182A (es) 2020-04-24 2021-04-23 Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.

Country Status (11)

Country Link
US (1) US20230192866A1 (es)
EP (1) EP4139357A1 (es)
JP (2) JP2023523006A (es)
KR (1) KR20230005281A (es)
CN (2) CN115698067A (es)
BR (1) BR112022021345A2 (es)
CA (1) CA3176186A1 (es)
IL (1) IL297443A (es)
MX (1) MX2022013182A (es)
TW (1) TW202206460A (es)
WO (1) WO2021215926A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025230410A1 (en) * 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
WO2013067054A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US20160068609A1 (en) * 2013-04-22 2016-03-10 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
SI3115376T1 (sl) 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
TWI717401B (zh) 2015-10-20 2021-02-01 南韓商東友精細化工有限公司 整合有偏光板之窗口基板、及製備該窗口基板之方法
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
US20210015859A1 (en) * 2017-12-08 2021-01-21 Fate Therapeutics, Inc. IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Also Published As

Publication number Publication date
JP2024177225A (ja) 2024-12-19
EP4139357A1 (en) 2023-03-01
KR20230005281A (ko) 2023-01-09
CA3176186A1 (en) 2021-10-28
CN115698067A (zh) 2023-02-03
AU2021261681A1 (en) 2022-12-08
IL297443A (en) 2022-12-01
JP2023523006A (ja) 2023-06-01
CN116731189A (zh) 2023-09-12
WO2021215926A1 (en) 2021-10-28
US20230192866A1 (en) 2023-06-22
TW202206460A (zh) 2022-02-16
BR112022021345A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
CY1123165T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
MX2023011145A (es) Terapia de combinacion que implica anticuerpos contra claudina 18.2 para el tratamiento del cancer.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
BR112019010356A2 (pt) molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MY150756A (en) Tumor theraphy with an anti-vegf antibody
PE20161096A1 (es) INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
PH12022550122A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
ZA201907225B (en) Treatment of her2 positive cancers
EP4644427A3 (en) Manabodies and methods of using
MX2021009514A (es) Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
PE20221830A1 (es) Anticuerpos especificos contra la claudina 18.2 tumoral
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
RU2016112421A (ru) Протиоопухолевое средство и усилитель противоопухолевого эффекта
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2025010212A (es) Uso de inmunoconjugados anti-ceacam5 para el tratamiento de canceres neuroendocrinos que expresan ceacam5
MY206650A (en) Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
MX2024014232A (es) Anticuerpo anti-b7h3 y usos del mismo
MX2022013182A (es) Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.